Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03790618 · ClinicalTrials.gov registry record · Phase 1
Effect of Stimulant Drugs on Social Perception
A Phase 1 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT03790618 is a Phase 1 study that has completed, run by University of Chicago. The registered enrollment target is 36 participants.
The verdict
NCT03790618, a Phase 1 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The study will improve our understanding of the "prosocial" effects of ± 3,4-Methylenedioxymethamphetamine (MDMA), relative to a prototypical stimulant, methamphetamine (MA). The investigators seek to characterize the "uniquely social" effects of MDMA.
Interventions
- DRUG 3,4-Methylenedioxymethamphetamine
- DRUG methamphetamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2016-06-01 |
| Est. Completion | 2018-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03790618
The ClinicalTrials.gov registry entry for NCT03790618 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 3,4-Methylenedioxymethamphetamine is the first listed.
NCT03790618 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03790618 about?
NCT03790618 is a clinical study titled "Effect of Stimulant Drugs on Social Perception". The study will improve our understanding of the "prosocial" effects of ± 3,4-Methylenedioxymethamphetamine (MDMA), relative to a prototypical stimulant, methamphetamine (MA). The investigators seek to characterize the "uniquely social" effects of MDMA.
What is the current status of trial NCT03790618?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2016-06-01. Estimated completion is 2018-08-01.
What interventions are being tested in trial NCT03790618?
The interventions under investigation include: 3,4-Methylenedioxymethamphetamine (DRUG), methamphetamine (DRUG).
Who is sponsoring clinical trial NCT03790618?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.